{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:33:57Z","timestamp":1782207237704,"version":"3.54.5"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>The mitogen-activated protein kinase (MAPK) signaling pathway is often studied in oncology as the most easily mentioned signaling pathway. This study aims to establish a new prognostic risk model of MAPK pathway related molecules in kidney renal clear cell carcinoma (KIRC) based on genome and transcriptome analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In our study, RNA-seq data were acquired from the KIRC dataset of The Cancer Genome Atlas (TCGA) database. MAPK signaling pathway-related genes were obtained from the gene enrichment analysis (GSEA) database. We used \u201cglmnet\u201d and the \u201csurvival\u201d extension package for LASSO (Least absolute shrinkage and selection operator) regression curve analysis and constructed a prognosis-related risk model. The survival curve and the COX regression analysis were used the \u201csurvival\u201d expansion packages. The ROC curve was plotted using the \u201csurvival ROC\u201d extension package. We then used the \u201crms\u201d expansion package to construct a nomogram plot. We performed a pan-cancer analysis of CNV (copy number variation), SNV (single nucleotide variant), drug sensitivity, immune infiltration, and overall survival (OS) of 14 MAPK signaling pathway-related genes using several analysis websites, such as GEPIA website and TIMER database. Besides, the immunohistochemistry and pathway enrichment analysis used The Human Protein Atlas (THPA) database and the GSEA method. Finally, the mRNA expression of risk model genes in clinical renal cancer tissues versus adjacent normal tissues was further verified by real-time quantitative reverse transcription (qRT-PCR).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We performed Lasso regression analysis using 14 genes and created a new KIRC prognosis-related risk model. High-risk scores suggested that KIRC patients with lower-risk scores had a significantly worse prognosis. Based on the multivariate Cox analysis, we found that the risk score of this model could serve as an independent risk factor for KIRC patients. In addition, we used the THPA database to verify the differential expression of proteins between normal kidney tissues and KIRC tumor tissues. Finally, the results of qRT-PCR experiments suggested large differences in the mRNA expression of risk model genes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study constructs a KIRC prognosis prediction model involving 14 MAPK signaling pathway-related genes, which is essential for exploring potential biomarkers for KIRC diagnosis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1077309","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T05:34:10Z","timestamp":1678426450000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Establishment of a new prognostic risk model of MAPK pathway-related molecules in kidney renal clear cell carcinoma based on genomes and transcriptomes analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Peizhi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zicheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leizuo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiechuan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingkun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangzhen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.10.008","article-title":"Global burden of urologic cancers, 1990-2013","volume":"71","author":"Dy","year":"2017","journal-title":"Eur Urol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/path.5022","article-title":"Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with pan-omics precision","volume":"244","author":"Hsieh","year":"2018","journal-title":"J Pathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21411","article-title":"Treatment of renal cell carcinoma: Current status and future directions","volume":"67","author":"Barata","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13943","article-title":"Systemic therapy in the management of localized and locally advanced renal cell carcinoma: Current state and future perspectives","volume":"26","author":"Berquist","year":"2019","journal-title":"Int J Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"B7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-020-00949-4","article-title":"The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy","volume":"13","author":"Yuan","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1126\/science.210501","article-title":"Generation of new mouse sarcoma viruses in cell culture","volume":"201","author":"Rapp","year":"1978","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1128\/MMBR.00031-10","article-title":"Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases","volume":"75","author":"Cargnello","year":"2011","journal-title":"Microbiol Mol Biol Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2012.02.003","article-title":"Ras family of small GTPases in immunity and inflammation","volume":"12","author":"Johnson","year":"2012","journal-title":"Curr Opin Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","first-page":":1618","DOI":"10.3390\/cancers11101618","article-title":"A comprehensive review on MAPK: A promising therapeutic target in cancer","volume":"11","author":"Braicu","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B12","first-page":"96","article-title":"The MAPK (ERK) pathway: Investigational combinations for the treatment of BRAF-mutated metastatic melanoma","volume":"38","author":"McCain","year":"2013","journal-title":"P T"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/16.16.4961","article-title":"MEK kinases are regulated by EGF and selectively interact with Rac\/Cdc42","volume":"16","author":"Fanger","year":"1997","journal-title":"EMBO J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3979","article-title":"Regulation of RAF protein kinases in ERK signalling","volume":"16","author":"Lavoie","year":"2015","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1243","article-title":"Keeping tumors out of the MAPK fitness zone","volume":"8","author":"Stern","year":"2018","journal-title":"Cancer Discovery"},{"key":"B16","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: the catalogue of somatic mutations in cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.acuro.2011.07.013","article-title":"[Role of mitogen-activated protein kinase (MAPK) in the sporadic renal cell carcinoma]","volume":"36","author":"Salinas-S\u00e1nchez","year":"2012","journal-title":"Actas Urol Esp"},{"key":"B18","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s13046-022-02460-9","article-title":"YTHDC1 is downregulated by the YY1\/HDAC2 complex and controls the sensitivity of ccRCC to sunitinib by targeting the ANXA1-MAPK pathway","volume":"41","author":"Li","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","article-title":"GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses","volume":"45","author":"Tang","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":":bbab173","DOI":"10.1093\/bib\/bbab173","article-title":"A new thinking: extended application of genomic selection to screen multiomics data for development of novel hypoxia-immune biomarkers and target therapy of clear cell renal cell carcinoma","volume":"22","author":"Gui","year":"2021","journal-title":"Brief Bioinform"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.18632\/aging.202601","article-title":"A bioinformatic analysis: the overexpression and clinical significance of FCGBP in ovarian cancer","volume":"13","author":"Wang","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B23","doi-asserted-by":"publisher","first-page":"6937475","DOI":"10.1155\/2020\/6937475","article-title":"A new prognostic risk model based on PPAR pathway-related genes in kidney renal clear cell carcinoma","volume":"2020","author":"Xu","year":"2020","journal-title":"PPAR Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.230","article-title":"Medical treatment of renal cancer: new horizons","volume":"115","author":"Greef","year":"2016","journal-title":"Br J Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":":198","DOI":"10.3390\/cells9010198","article-title":"Targeting aberrant RAS\/RAF\/MEK\/ERK signaling for cancer therapy","volume":"9","author":"Degirmenci","year":"2020","journal-title":"Cells"},{"key":"B26","doi-asserted-by":"publisher","first-page":"115180","DOI":"10.1016\/j.bcp.2022.115180","article-title":"Rac1 as a therapeutic anticancer target: Promises and limitations","volume":"203","author":"Bailly","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3599832","DOI":"10.1155\/2022\/3599832","article-title":"SHC1 promotes lung cancer metastasis by interacting with EGFR","volume":"2022","author":"Yang","year":"2022","journal-title":"J Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.759818","article-title":"hZIP1 inhibits progression of clear cell renal cell carcinoma by suppressing NF-kB\/HIF-1\u03b1 pathway","volume":"11","author":"Zhan","year":"2021","journal-title":"Front Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2020.1850609","article-title":"MAPK1\/3 kinase-dependent ULK1 degradation attenuates mitophagy and promotes breast cancer bone metastasis","volume":"17","author":"Deng","year":"2021","journal-title":"Autophagy"},{"key":"B30","doi-asserted-by":"publisher","first-page":"11468","DOI":"10.26355\/eurrev_202011_23759","article-title":"MiR-129 reduces CDDP resistance in gastric cancer cells by inhibiting MAPK3","volume":"24","author":"Cao","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.7150\/jca.27281","article-title":"Comprehensive analysis of BAP1 somatic mutation in clear cell renal cell carcinoma to explore potential mechanisms in silico","volume":"9","author":"Jin","year":"2018","journal-title":"J Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1593\/neo.131660","article-title":"Synthetic lethality screen identifies RPS6KA2 as modifier of epidermal growth factor receptor activity in pancreatic cancer","volume":"15","author":"Milosevic","year":"2013","journal-title":"Neoplasia"},{"key":"B33","doi-asserted-by":"publisher","first-page":"6782","DOI":"10.1038\/ncomms7782","article-title":"The E3 ubiquitin ligase Trim7 mediates c-Jun\/AP-1 activation by ras signalling","volume":"6","author":"Chakraborty","year":"2015","journal-title":"Nat Commun"},{"key":"B34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1139\/o11-092","article-title":"Histone H3 phosphorylation, immediate-early gene expression, and the nucleosomal response: a historical perspective","volume":"90","author":"Healy","year":"2012","journal-title":"Biochem Cell Biol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00541-y","article-title":"Metabolic barriers to cancer immunotherapy","volume":"21","author":"DePeaux","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.70149","article-title":"ALKBH5\/MAP3K8 axis regulates PD-L1+ macrophage infiltration and promotes hepatocellular carcinoma progression","volume":"18","author":"You","year":"2022","journal-title":"Int J Biol Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.779290","article-title":"MAP3K8 is a prognostic biomarker and correlated with immune response in glioma","volume":"8","author":"Ren","year":"2021","journal-title":"Front Mol Biosci"},{"key":"B38","doi-asserted-by":"publisher","first-page":"101830","DOI":"10.1016\/j.mcp.2022.101830","article-title":"circNup188\/miR-760-3p\/Map3k8 axis regulates inflammation in cerebral ischemia","volume":"64","author":"Zhang","year":"2022","journal-title":"Mol Cell Probes"},{"key":"B39","doi-asserted-by":"publisher","first-page":":49","DOI":"10.3892\/or.2023.8486","article-title":"GBP2 promotes clear cell renal cell carcinoma progression through immune infiltration and regulation of PD\u2212L1 expression via STAT1 signaling","volume":"49","author":"Ye","year":"2023","journal-title":"Oncol Rep"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2016.03.009","article-title":"TRAF2 multitasking in TNF receptor-induced signaling to NF-\u03baB, MAP kinases and cell death","volume":"116","author":"Borghi","year":"2016","journal-title":"Biochem Pharmacol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02024","article-title":"TRAF2 controls death receptor-induced caspase-8 processing and facilitates proinflammatory signaling","volume":"10","author":"Kreckel","year":"2019","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-00583-7","article-title":"TRAF2 regulates T cell immunity by maintaining a Tpl2-ERK survival signaling axis in effector and memory CD8 T cells","volume":"18","author":"Xie","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.901671","article-title":"Comprehensive analysis of senescence characteristics defines a novel prognostic signature to guide personalized treatment for clear cell renal cell carcinoma","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1125","article-title":"RAS\/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: Therapeutic cooperation between MEK and PD-1\/PD-L1 immune checkpoint inhibitors","volume":"22","author":"Loi","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.3892\/etm.2020.8454","article-title":"ERK\/MAPK signalling pathway and tumorigenesis","volume":"19","author":"Guo","year":"2020","journal-title":"Exp Ther Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1077309\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T05:34:16Z","timestamp":1678426456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1077309\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,10]]},"references-count":45,"alternative-id":["10.3389\/fonc.2023.1077309"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1077309","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,10]]},"article-number":"1077309"}}